-
Hyperthermia-Induced BRCA2 Reduction Sensitizes Ovarian Canc
2026-04-21
Mei et al. reveal that hyperthermia can transiently reduce BRCA2 protein levels in BRCA2-proficient ovarian carcinoma, thereby sensitizing otherwise resistant cells to PARP inhibitor therapy. This mechanistic insight supports rational combination strategies for overcoming PARP inhibitor resistance in solid tumors.
-
Biotin (Vitamin B7) in Advanced Protein Biotinylation Workfl
2026-04-21
Biotin (Vitamin B7) is transforming protein labeling and metabolic pathway analysis with superior specificity and robust avidin-streptavidin affinity. This article details optimized biotinylation protocols, troubleshooting insights, and experimental advantages, bridging new research on adaptor protein mechanisms to practical laboratory workflows.
-
Lenalidomide (CC-5013): Immune-Epigenetic Synergy in Myeloma
2026-04-20
Explore how Lenalidomide (CC-5013) catalyzes a new era in multiple myeloma research through immune-epigenetic synergy. This article delivers mechanistic insights, protocol guidance, and strategic recommendations for translational scientists, anchored by breakthrough findings on DOT1L inhibition. Go beyond routine workflows to unlock the full translational impact of APExBIO’s Lenalidomide (CC-5013).
-
Next-Generation mRNA Tracking: EZ Cap Cy5 Luciferase (5-moUT
2026-04-20
Discover how EZ Cap Cy5 Firefly Luciferase mRNA (5-moUTP) enables high-fidelity, dual-modality tracking and quantification of mRNA delivery and translation. This article uniquely bridges molecular engineering with advanced assay optimization, offering insights beyond standard workflow guides.
-
NHS-Biotin: Precision Biotinylation for Intracellular Protei
2026-04-19
NHS-Biotin enables high-efficiency, low-steric hindrance biotinylation of antibodies and proteins, optimizing workflows for both intracellular and multimeric protein applications. By leveraging its unique membrane-permeable chemistry, researchers can advance protein detection, purification, and engineering strategies beyond conventional biotinylation reagents.
-
Mitoxantrone Disrupts ERα Function via DBD-LBD Interface Tar
2026-04-18
This study identifies mitoxantrone as a novel modulator of estrogen receptor alpha (ERα), acting at the DBD-LBD interface to induce receptor degradation. The findings expand the use of this DNA topoisomerase II inhibitor beyond DNA damage, highlighting an allosteric approach to overcoming resistance in hormone-driven cancers.
-
Vesicular Trafficking and Matriptase in EGF-Driven Cancer In
2026-04-17
Ye et al. (2024) uncover a previously unappreciated mechanism in which EGF induces endocytosis and acidic activation of matriptase, followed by its exosomal secretion. This process triggers a secondary wave of oncogenic signaling via HGF/c-Met in skin and breast cancer, highlighting new opportunities for targeted intervention and mechanistic study.
-
Imatinib (STI571): Unveiling Signal Transduction Specificity
2026-04-16
Explore how Imatinib (STI571) empowers precise signal transduction research through advanced kinase inhibition. This article uniquely connects cutting-edge mass spectrometry imaging innovations to robust kinase assay design, offering new practical insights for cancer biology researchers.
-
Bestatin (Ubenimex): Precision Tool for Aminopeptidase Resea
2026-04-15
Bestatin (Ubenimex) is the gold-standard aminopeptidase inhibitor for dissecting protease-mediated pathways in multidrug resistance and cancer research. This guide delivers actionable workflows, troubleshooting insights, and protocol enhancements to maximize your experimental success with APExBIO’s high-purity Bestatin.
-
Pulsed Plasma Degradation of Sulfamonomethoxine: Kinetics, B
2026-04-14
This study details the degradation of the veterinary antibiotic Sulfamonomethoxine (SMM) in aqueous solution using pulsed plasma discharge. It identifies reaction kinetics, by-product profiles, and evaluates the ecotoxicological impact of treated effluent on green algae, providing a framework for advanced removal strategies in environmental and veterinary contexts.
-
AZD0156: Workflow-Driven Advances with an ATM Kinase Inhibit
2026-04-13
AZD0156 is redefining DNA damage response research as a potent and selective ATM kinase inhibitor, empowering precise modulation of double-strand break repair and checkpoint control. This guide delivers actionable workflows, troubleshooting strategies, and comparative insights for maximizing AZD0156’s impact in cancer therapy research.
-
Cycloastragenol Enhances Radiotherapy for Lung Cancer Brain
2026-04-13
This study reveals that cycloastragenol (CAG) not only sensitizes brain metastatic lung tumors to radiotherapy but also mitigates radiation-induced neuroinflammation and injury. Through in vivo imaging, transcriptomic analyses, and mechanistic validation, the paper establishes CAG as a promising adjuvant for improving efficacy and safety of brain metastasis treatment.
-
Cy3 NHS ester (non-sulfonated): Technical Guide for Labeling
2026-04-12
Cy3 NHS ester (non-sulfonated) addresses the need for robust, high-sensitivity fluorescent labeling of amino groups in proteins, peptides, and oligonucleotides. It is ideally suited for workflows demanding reproducible orange-range fluorescence and compatibility with organic co-solvents. This product should not be used where water-only labeling conditions are required, particularly with delicate or highly sensitive proteins.
-
GABRA1 Frameshift Variants Disrupt GABAA Receptor Proteostas
2026-04-12
This study elucidates how four clinical frameshift mutations in the GABRA1 gene compromise GABAA receptor folding, trafficking, and surface expression, leading to impaired receptor function. The findings provide mechanistic insight into genetic epilepsy pathogenesis and highlight cell surface proteostasis as a critical vulnerability.
-
Troglitazone: PPARγ Agonist Workflows for Diabetes & Oncolog
2026-04-11
Troglitazone’s dual PPARγ/α agonist activity offers researchers a unique tool for dissecting metabolic and tumor microenvironment pathways. This article translates recent breakthroughs and validated protocols into actionable guidance for integrating Troglitazone in type 2 diabetes and anti-tumor agent workflows.